Entasis Therapeutics Garners $50,000,000 Series B Funding

  • Feed Type
  • Date
    4/5/2016
  • Company Name
    Entasis Therapeutics
  • Mailing Address
    35 Gatehouse Drive Waltham, MA 02451 USA
  • Company Description
    Entasis Therapeutics is developing a portfolio of innovative cures for serious drug-resistant bacterial infections, a global health crisis affecting the lives of millions of patients. Our deep pipeline of novel clinical and preclinical antibacterial programs is designed to revolutionize the way physicians treat serious bacterial diseases.
  • Website
    http://www.entasistx.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $50,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    The proceeds from this financing will enable us to further advance our portfolio of innovative anti-infective products directed at addressing the global health crisis created by the rise in antibiotic resistance in a fundamentally differentiated way.
  • M&A Terms
  • Venture Investor
    Clarus Ventures
  • Venture Investor
    Frazier Healthcare Partners
  • Venture Investor
    Novo Ventures
  • Venture Investor
    Eventide Asset Management
  • Venture Investor
    AstraZeneca

Trending on Xconomy